PDL BioPharma pioneered the humanization of monoclonal antibodies
and, by so doing, enabled the discovery
of a new generation of targeted treatments for cancer and immunologic diseases.
PDL BioPharma Announces Settlement of Keytruda Patent Infringement Lawsuit with Merck
PDL BioPharma to Hold Annual Meeting of Stockholders on June 9, 2017
PDL BioPharma to Present at the Oppenheimer 27th Annual Healthcare Conference
PDL BioPharma to Present at Two Upcoming Investor Conferences
PDL BioPharma Announces Fourth Quarter and Year End 2016 Financial Results